| ²é¿´: 602 | »Ø¸´: 3 | ||
| ±¾Ìû²úÉú 1 ¸ö ²©Ñ§EPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||
abcd888898Òø³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÇóÖúCAS£º615258-40-7µÄÐòÁУ¬ÓÐЧÆÚ40Ìì
|
|
| ´ó¼Ò°ïæ²éÒ»ÏÂCAS£º615258-40-7µÄÐòÁС£ |
» ²ÂÄãϲ»¶
²ÄÁÏÓ뻯¹¤371Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
328·Öµ÷¼Á
ÒѾÓÐ4È˻ظ´
295Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
081700£¬311£¬Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
283·ÖÇóµ÷¼Á
ÒѾÓÐ6È˻ظ´
0854Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
332Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
284Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
304Çóµ÷¼Á£¨085602£¬¹ýËļ¶£¬Ò»Ö¾Ô¸985£©
ÒѾÓÐ11È˻ظ´
0817»¯Ñ§¹¤³ÌÓë¼¼ÊõÇóµ÷¼Á£¬Ò»Ö¾Ô¸Öк£Ñó319
ÒѾÓÐ10È˻ظ´
abcd888898
Òø³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 646.8
- É¢½ð: 11
- Ìû×Ó: 326
- ÔÚÏß: 39.4Сʱ
- ³æºÅ: 417550
- ×¢²á: 2007-07-01
- ÐÔ±ð: GG
- רҵ: Ò©Æ·×¢²á
4Â¥2011-07-21 18:26:46
hblgczy
ÖÁ×ðľ³æ (ÎÄ̳¾«Ó¢)
- ²©Ñ§EPI: 667
- Ó¦Öú: 81 (³õÖÐÉú)
- ½ð±Ò: 26583.8
- É¢½ð: 168
- ºì»¨: 37
- ɳ·¢: 38
- Ìû×Ó: 11563
- ÔÚÏß: 1274Сʱ
- ³æºÅ: 348922
- ×¢²á: 2007-04-19
- ÐÔ±ð: GG
- רҵ: µç»¯Ñ§

2Â¥2011-07-21 17:18:20
hblgczy
ÖÁ×ðľ³æ (ÎÄ̳¾«Ó¢)
- ²©Ñ§EPI: 667
- Ó¦Öú: 81 (³õÖÐÉú)
- ½ð±Ò: 26583.8
- É¢½ð: 168
- ºì»¨: 37
- ɳ·¢: 38
- Ìû×Ó: 11563
- ÔÚÏß: 1274Сʱ
- ³æºÅ: 348922
- ×¢²á: 2007-04-19
- ÐÔ±ð: GG
- רҵ: µç»¯Ñ§
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
abcd888898(½ð±Ò+3): 2011-07-21 18:27:39
|
Ó¢ÎÄÆ·Ãû denosumab Ãû³ÆÀ´Ô´ p-INNList-94,2005;r-INNList-56,2006; ±ð¡¡¡¡Ãû AMG 162 »¯Ñ§±íÊö immunoglobulin G2, anti-(human tumor necrosis factor ligand superfamily member 11 (human osteoclast differentiation factor))(human monoclonal AMG162 heavy chain), disulfide with human monoclonal AMG162 light chain, dimer CAµÇ¼ÇºÅ 615258-40-7 ·Ö ×Ó Ê½ C6404H9908N1724O2004S50 Æ·ÖÖÀà±ð ¿¹¹ÇÖÊÊèËÉÒ©>µ¥¿Ë¡¿¹ÌåÀà; immunological agent; ¼ò½é ÉÏÊУ¨Amgen£¬ÃÀ¹ú£© |

3Â¥2011-07-21 17:19:01














»Ø¸´´ËÂ¥